PUBLICATIONS - New from Clinica Reports - New Devices for Cardiovascular and Heart Disease Volume 2: Management of cardiac rhythm disorders and end-stage cardiac disease
This article was originally published in Clinica
Executive Summary
At the dawn of the new millennium, cardiovascular disease (CVD) remains the leading cause of premature death and morbidity in the industrialised nations. World Health Organisation (WHO) statistics show that in 1999 approximately 17 million deaths worldwide were attributable to CVD, of which 9 million were in the developed nations of the world.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.